1. EVALUATION OF RECEPTOR FOR ADVANCED GLYCATION END PRODUCT /HIGH-MOBILITY GROUP BOX 1 (RAGE/HMGB1) EXPRESSION STATUS AND ITS PROGNOSTIC VALUE IN BREAST CANCER.
- Author
-
Shimaa El-Shafey Soliman, Mona Salah El-din Habib, Serag El-Dien, Marwa M., Gohar, Suzy Fawzy, and Alhassanin, Suzan A.
- Subjects
- *
ADVANCED glycation end-products , *BREAST cancer , *GROUP products (Mathematics) , *PATHOLOGY - Abstract
Sucess in breast cancer treatment is not built only on diversity but on clinical relevance to tumor pathogenesis. So, gathering of many prognositic biomarkers involved in cancer progression could yield new treatment modalities in order to maitain good quality of life for patients .The receptor for advanced glycation end product (RAGE) and its ligand the high-mobility group box 1 (HMGB1) protein seem to play a role in many cancers, their cross-talk affects breast cancer behaviour. The aim of this study was to investigate the tissue RAGE and HMGB1 expression levels and their association with clinicopathological features and overall survival in breast cancer patients. Tissue RAGE and HMGB1 mRNA levels were measured by real time-polymerase chain reaction (RT-PCR). Results showed tissue RAGE and HMGB1 displayed significant higher expression levels compared to benign group. RAGE and HMGB1 expression levels in breast cancer tissues were significantly associated with high tumour grade, lymph node metastasis, stage III wih no significant relation to the molecular type of tumor nor overall survival. RAGE-HMGB1 system seems to be linked to breast cancer which may represent a prognostic biomarker of clinical and theraputic significance. [ABSTRACT FROM AUTHOR]
- Published
- 2019